Medical Oncology

, Volume 29, Issue 2, pp 1127–1133

Clinical characteristics and prognostic factors in Chinese patients with Hodgkin’s lymphoma

  • Ying-Jie Zhu
  • Yue-Li Sun
  • Yi Xia
  • Wen-Qi Jiang
  • Jia-Jia Huang
  • Hui-Qiang Huang
  • Tong-Yu Lin
  • Zhong-Zhen Guan
  • Zhi-Ming Li
Original Paper

Abstract

The aim of our study is to investigate the clinical characteristics and prognostic factors in Chinese Hodgkin’s lymphoma patients. It is known that clinical characteristics and epidemiology of Hodgkin’s lymphoma in China are different from Western countries. In total, 137 consecutive, previously untreated patients with Hodgkin’s lymphoma at Sun Yat-Sen University Cancer Center were enrolled. Among these patients, 92 were male and 45 were female, with a median age of 28 (range: 2–76) years. The bimodal age curve of classical Hodgkin’s lymphoma analyzed from our patients was not obvious as the Western population, showing an early peak in 25 years and a second peak in 45 years. Most of the patients (41.6%) were classified as nodular sclerosis classic Hodgkin’s lymphoma. Results showed that the 5-year overall survival, event-free survival, and disease-free survival rates were 97.7, 85.0, and 94.0%, respectively. Lymphopenia at diagnosis was related to poorer overall survival (P = 0.015) and event-free survival (P < 0.001) in all-stage Hodgkin’s lymphoma patients. Multivariate analysis showed that lymphopenia as an independent unfavorable prognostic factor influenced event-free survival (P = 0.015). The international prognostic score ≥ 5 was also the only independent prognostic factor of disease-free survival in advanced-stage patients (P = 0.046). Our findings demonstrated that some clinical characteristics of Hodgkin’s lymphoma in China were different from those in the Western countries. Lymphopenia was an effective prognostic predictor in both early stage and advanced stage.

Keywords

Hodgkin’s lymphoma Prognosis Lymphopenia International prognostic score 

References

  1. 1.
    Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC; 2008.Google Scholar
  2. 2.
    Punnett A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects. Semin Radiat Oncol. 2010;20:30–44.PubMedCrossRefGoogle Scholar
  3. 3.
    Glaser SL, Jarrett RF. The epidemiology of Hodgkin’s disease. Bailliere’s Clin Haematol. 1996;9:401–16.CrossRefGoogle Scholar
  4. 4.
    Liang R, et al. Hodgkin’s disease in Hong Kong Chinese. Hematol Oncol. 1989;7:395–403.PubMedCrossRefGoogle Scholar
  5. 5.
    Ji X, Li W. Malignant lymphomas in Beijing. J Environ Pathol Toxicol Oncol. 1992;11:327–9.PubMedGoogle Scholar
  6. 6.
    Aisenberg AC. Problems in Hodgkin’s disease management. Blood. 1999;93:761–79.PubMedGoogle Scholar
  7. 7.
    Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. New Engl J Med. 1998;339:1506–14.PubMedCrossRefGoogle Scholar
  8. 8.
    Henry-Amar M, et al. Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC lymphoma cooperative group. Ann Intern Med. 1991;114:361–5.PubMedGoogle Scholar
  9. 9.
    Tubiana M, et al. Prognostic significance of the number of involved areas in the early stages of Hodgkin’s disease. Cancer. 1984;54:885–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Tubiana M, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC lymphoma group controlled clinical trials: 1964–1987. Blood. 1989;73:47–56.PubMedGoogle Scholar
  11. 11.
    Duhmke E, et al. Randomized trial with early-stage Hodgkin’s disease testing 30 Gy vs. 40 Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys. 1996;36:305–10.PubMedCrossRefGoogle Scholar
  12. 12.
    Cheson BD, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI sponsored international working group. J Clin Oncol 1999;17:1244.Google Scholar
  13. 13.
    Grillo-Lopez AJ, et al. Response criteria for NHL: importance of ‘normal’ lymph node size and correlations with response rates. Ann Oncol. 2000;11:399–408.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.Google Scholar
  15. 15.
    Smolewski P, et al. Prognostic factors in Hodgkin’s disease: multivariate analysis of 327 patients from a single institution. Clin Cancer Res. 2000;6:1150–60.PubMedGoogle Scholar
  16. 16.
    Josting A, et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin lymphoma study group. Blood. 2000;96:1280–6.PubMedGoogle Scholar
  17. 17.
    Tomita Y, et al. Epstein-Barr virus in Hodgkin’s disease patients in Japan. Cancer. 1996;77:186–92.PubMedCrossRefGoogle Scholar
  18. 18.
    Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Ferme C, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. New Engl J Med. 2007;357:1916–27.PubMedCrossRefGoogle Scholar
  20. 20.
    Noordijk EM, et al. Combined-modality therapy for clinical stage I or II Hodgkin’s lymphoma: long-term results of the European organisation for research and treatment of cancer H7 randomized controlled trials. J Clin Oncol. 2006;24:3128–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Engert A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s lymphoma: results of the HD8 trial of the German Hodgkin’s lymphoma study group. J Clin Oncol. 2003;21:3601–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Herbst C, et al. Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review. Haematologica. 2010;95:494–500.PubMedCrossRefGoogle Scholar
  23. 23.
    Itoh K, et al. Prognostic analysis and a new risk model for Hodgkin lymphoma in Japan. Int J Hematol. 2010;91:446–55.PubMedCrossRefGoogle Scholar
  24. 24.
    Tan WY, et al. Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases. Ai zheng. 2007;26:1360–4.PubMedGoogle Scholar
  25. 25.
    Franklin J, et al. Is the international prognostic score for advanced stage Hodgkin’s disease applicable to early stage patients? German Hodgkin lymphoma study group. Ann Oncol. 2000;11:617–23.PubMedCrossRefGoogle Scholar
  26. 26.
    Straus DJ, et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol. 1990;8:1173–86.PubMedGoogle Scholar
  27. 27.
    Garcia R, et al. Serum lactate dehydrogenase level as a prognostic factor in Hodgkin’s disease. Br J Cancer. 1993;68:1227–31.PubMedCrossRefGoogle Scholar
  28. 28.
    Shipp M, et al. A predictive model for aggressive non-Hodgkin’s lymphoma. The international non-Hodgkin’s lymphoma prognostic factors project. New England J Med. 1993;329:987–94.CrossRefGoogle Scholar
  29. 29.
    Siddiqui M, et al. Absolute lymphocyte count predicts overall survival in follicular lymphomas. Br J Haematol. 2006;134:596–601.PubMedCrossRefGoogle Scholar
  30. 30.
    Behl D, et al. Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007;137:409–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Kim DH, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007;21:2227–30.PubMedCrossRefGoogle Scholar
  32. 32.
    Plonquet A, et al. Peripheral blood natural killer cell count is associated with clinical outcome in patients with a IPI 2–3 diffuse large B-cell lymphoma. Ann Oncol. 2007;18:1209–15.PubMedCrossRefGoogle Scholar
  33. 33.
    Cox MC, et al. Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008;49:1745–51.PubMedCrossRefGoogle Scholar
  34. 34.
    Oki Y, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol. 2008;81:448–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Porrata LF, et al. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2009;84:93–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Ray-Coquard I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69:5383–91.PubMedCrossRefGoogle Scholar
  37. 37.
    Saito T, et al. Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res. 1999;5:1263–73.PubMedGoogle Scholar
  38. 38.
    Goldrath AW, Bevan MJ. Selecting and maintaining a diverse T-cell repertoire. Nature. 1999;402:255–62.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Ying-Jie Zhu
    • 1
    • 2
  • Yue-Li Sun
    • 1
    • 2
  • Yi Xia
    • 1
    • 2
  • Wen-Qi Jiang
    • 1
    • 2
  • Jia-Jia Huang
    • 1
    • 2
  • Hui-Qiang Huang
    • 1
    • 2
  • Tong-Yu Lin
    • 1
    • 2
  • Zhong-Zhen Guan
    • 1
    • 2
  • Zhi-Ming Li
    • 1
    • 2
  1. 1.State Key Laboratory of Oncology in Southern ChinaSun Yat-Sen UniversityGuangzhou, GuangdongPeople’s Republic of China
  2. 2.Department of Medical Oncology, State Key Laboratory of Oncology in Southern ChinaSun Yat-Sen University Cancer CenterGuangzhouPeople’s Republic of China

Personalised recommendations